國立虎尾科技大學 |

Pediatric Cancer Therapeutics Development

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Pediatric Cancer Therapeutics Development/ edited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith.
其他作者:	Smith, Franklin O.
面頁冊數:	VI, 181 p. 21 illus., 19 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pediatrics. -
電子資源:	https://doi.org/10.1007/978-3-031-06357-2
ISBN:	9783031063572

Pediatric Cancer Therapeutics Development
Pediatric Cancer Therapeutics Development[electronic resource] /edited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith. - 1st ed. 2022. - VI, 181 p. 21 illus., 19 illus. in color.online resource. - Pediatric Oncology,2191-0812. - Pediatric Oncology,.

History of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino. .

This book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.

ISBN: 9783031063572

Standard No.: 10.1007/978-3-031-06357-2doiSubjects--Topical Terms:

644839
Pediatrics.

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Pediatric Cancer Therapeutics Development
LDR:02927nam a22004095i 4500 001 1085638
003 DE-He213
005 20221118074033.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783031063572 $9 978-3-031-06357-2
024 7 $a 10.1007/978-3-031-06357-2 $2 doi
035 $a 978-3-031-06357-2
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Pediatric Cancer Therapeutics Development $h [electronic resource] / $c edited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a VI, 181 p. 21 illus., 19 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Pediatric Oncology, $x 2191-0812
505 0 $a History of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino. .
520 $a This book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.
650 0 $a Pediatrics. $3 644839
650 0 $a Oncology. $3 593951
700 1 $a Smith, Franklin O. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 784414
700 1 $a Reaman, Gregory H. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 784413
700 1 $a DiMartino, Jorge. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1392181
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783031063565
776 0 8 $i Printed edition: $z 9783031063589
776 0 8 $i Printed edition: $z 9783031063596
830 0 $a Pediatric Oncology, $x 1613-5318 $3 1255194
856 4 0 $u https://doi.org/10.1007/978-3-031-06357-2
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)